Abstract
Objective: To evaluate the contribution of carboprost in the prevention of postpartum haemorrhage in patients with haemorrhagic risk factors. Patients and Method: We conducted an analytical study at the Teaching Hospital of Angré (January 1, 2020-December 31, 2022) on vaginal births with one or more of the following bleeding risk factors: age ≥ 35 years, multiparity, overdistension uterine. Group 1 consisted of postpartum patients who received only oxytocin. Those in group 2 received oxytocin and another uterotonic: carboprost. Blood loss was quantified postpartum. The chi 2 statistical test was used to compare the 2 groups at the threshold α = 5%. Results: We identified 4,203 vaginal deliveries including 823 hemorrhagic risk factors meeting the study criteria. Blood loss was greater in patients who had received only oxytocin, particularly the risk factors for multiparity and uterine overdistension [age 35 years (17.46% versus 8.89% p=0.11); multiparous (14.15% against 5.56% p=0.003); patients with uterine overdistension (23.71% versus 9.67% p=0.00001)]. Conclusion: The synergy of 2 utero tonics, namely oxytocin and carboprost, in patients with hemorrhagic risk factors, in particular multiparity and uterine overdistension, contributes to reducing postpartum bleeding. Adding carboprost is a good alternative to preventing postpartum hemorrhage in parturients at higher risk.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call